Trial Profile
A Phase 1 Clinical Trial to Evaluate the Immunogenicity of AIDSVAX B/E Bivalent gp120 Vaccine and MVA/HIV62B in Healthy, HIV-1-Uninfected Adult Participants Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV gp120 vaccine (Primary) ; MVA-HIV62 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 03 Jul 2021 Results published in the Vaccine
- 24 Jan 2020 Status changed from active, no longer recruiting to completed.
- 10 Sep 2019 Planned End Date changed from 30 Sep 2019 to 17 Feb 2020.